CZP Q4W
Phase 3Biologic
UCBCZP Q4W is one of 71 biologic programs targeting Arthritis. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
70
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
159 competitors in Arthritis
#DrugCompanyPhaseTrials
1Cosentyx
NovartisPhase 3
Taltz
Eli LillyPhase 3
Stelara
Johnson & JohnsonPhase 3
Bimzelx
UCBPhase 3
Ilaris
NovartisPhase 3
Remicade
OOrganon and Co
Phase 3
Kenalog
BBassett Healthcare
Phase 3
Kenalog
BBausch Health Americas, Inc.
Phase 3
Toradol
JJavelin Pharmaceuticals
Phase 3
Open-Label Adalimumab
AbbViePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CZP Q4W. EMBL-EBI & Wellcome Sanger Institute.
- [4]